Literature DB >> 9850052

Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.

C E Herzog1, K A Holmes, L M Tuschong, R Ganapathi, L A Zwelling.   

Abstract

Numerous chemotherapeutic agents act via stabilization of a topoisomerase (topo) II-DNA complex. HL-60/AMSA, a human leukemia cell line, is resistant to intercalator-mediated DNA complex formation and cytotoxicity. HL-60/AMSA contains a mutant form of topo IIalpha that was thought to explain this resistance. However, our present data show that expression of topo IIbeta RNA in HL-60/AMSA is only 10% of that in HL-60, and topo IIbeta protein levels are undetectable. Southern analysis of topo IIbeta shows no differences in gene dosage between the two cell lines but does show differences in the restriction patterns. These data suggest that decreased topo IIbeta expression may contribute to the intercalator resistance of HL-60/AMSA cells.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9850052

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  11 in total

1.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

2.  XK469, a selective topoisomerase IIbeta poison.

Authors:  H Gao; K C Huang; E F Yamasaki; K K Chan; L Chohan; R M Snapka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

3.  Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance.

Authors:  Suzan McNamara; Hongling Wang; Nessrine Hanna; Wilson H Miller
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

Review 4.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

5.  Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

Authors:  Chun-Nam Lok; Alexander J Lang; Shelagh E L Mirski; Susan P C Cole
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

6.  Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.

Authors:  Z Zhou; L A Zwelling; R Ganapathi; E S Kleinerman
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

7.  Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.

Authors:  Guo-Xin Hou; Panpan Liu; Jing Yang; Shijun Wen
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

8.  Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Authors:  Toshiyuki Kozuki; Kenichi Chikamori; Marius D Surleac; Marius A Micluta; Andrei J Petrescu; Eric J Norris; Paul Elson; Gerald A Hoeltge; Dale R Grabowski; Andrew C G Porter; Ram N Ganapathi; Mahrukh K Ganapathi
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

9.  DNA-AP sites generation by etoposide in whole blood cells.

Authors:  Emilio Rojas; Patricia Mussali; Efrain Tovar; Mahara Valverde
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

10.  Mechanisms regulating resistance to inhibitors of topoisomerase II.

Authors:  Ram N Ganapathi; Mahrukh K Ganapathi
Journal:  Front Pharmacol       Date:  2013-08-01       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.